Advertisement EY mid banner
RealVNC mid-banner general
Advertisement: Cambridge Network
Advertisement: TTP
Advertisement: Mogrify
Mid banner advertisement: BDO
Advertisement Cambridge China Centre
Advertisement: Bradfield Centre mid
Advertisement: RSM
Advertisement: Wild Knight Vodka
RealVNC mid banner careers
ARM Innovation Hub
Barr Ellison Solicitors – commercial property
23 February, 2006 - 10:26 By Staff Reporter

Domino role in haemophilia project

Domino Integrated Solutions Group, part of Domino Printing Sciences, has announced the implementation of the world’s first fully integrated traceable haemophilia drug administration programme for the pharmaceutical industry.Domino Integrated Solutions Group, part of Domino Printing Sciences, has announced the implementation of the world’s first fully integrated traceable haemophilia drug administration programme for the pharmaceutical industry.

A successful trial in Ireland has proved suitable for global adoption. The programme is a joint initiative between Domino, the National Centre for Hereditary Coagulation Disorders in Ireland (NCHCD) and global supply chain standards organisation, GS1.

The Irish pilot has involved the 100 track and trace of drugs administered to haemophilia patients at St James’s Hospital in Dublin. It allows secure deliveries and stock optimisation in full respect of cool chain logistics and patient safety.

The drug track and trace system uses GS1’s latest electronic bar coding technology to trace expensive and time-sensitive Clotting Factor Conc-entrates, the product used to treat haemophiliacs.

The integrated EPC technology (electronic product code) assigns a unique number to every single item that rolls off a manufacturing line, allowing every company in the supply chain to track products at the individual item of use level.

Following a two year trial period, the solution has been successfully implemented and is ready to be rolled out nationally.

The use of unique serial numbering and bar coding on each vial box enables automatic electronic data collection and processing that will further result in safer patient treatment.

The trial was the brainchild of Dr Barry White, director of the NCHCD, whose vision was to establish a comprehensive and fully traceable drug administration programme, from manufacturer through to patient.

His concerns were in response to the publication of the Lindsay Report, which reported the infection of hundreds of haemophiliacs with HIV and Hepatitis C as a result of receiving contaminated blood products.

He said: “The contamination of blood products was one of the most catastrophic medical complications of the last century and some of the infections were due to defects in the supply chain. There were considerable difficulties in identifying who had received the infected CFCs and in recalling all the contaminated products.”

Tony Walsh, European business development manager at the Integrated Solutions Group of Domino said: “This is a tremendous breakthrough and heralds a new area for patient safety. Tracing blood products accurately throughout the supply chain is absolutely vital to ensure the safer administration of haemophilia drugs.

“This solution will guarantee that the right patient receives the right dosage of the right blood product, at the right temperature and at the right time, every time.”

Add new comment

Newsletter Subscription

Stay informed of the latest news and features